Results 41 to 50 of about 5,144 (141)

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Dermatology and Therapy, 2023
Background Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation.
Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Annalise Hilts, Patrick Lefebvre, Steven R. Feldman   +6 more
doaj   +1 more source

Reply

Arthritis &Rheumatology, EarlyView.
Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +6 more
wiley   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, EarlyView.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Chinese herbal medicine (Guben Qushi Huayu formula) combined with Ixekizumab in reducing psoriasis vulgaris relapse: Protocol for a mixed-methods research study

Frontiers in Pharmacology
IntroductionPsoriasis vulgaris (PV) is an inflammatory, chronically relapsing dermatological disease associated with significant comorbidities. Ixekizumab is recommended as the first-line therapy for severe PV, but encounters persistent challenges with ...
Ziqing Li, Kewen Guan, Hao Deng, Shuyan Ye, Jingwen Deng, Danni Yao, Yuhong Yan, Haiming Chen, Chuanjian Lu, Chuanjian Lu, Chuanjian Lu, Jingjie Yu   +11 more
doaj   +1 more source

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Arthritis Research & Therapy, 2020
Background The long-term safety was assessed in patients with psoriatic arthritis who were treated with ixekizumab in three clinical trials (SPIRIT-P1/-P2/-P3). Methods Integrated safety data from three trials (controlled and uncontrolled), including two
Bernard Combe, Proton Rahman, Hideto Kameda, Juan D. Cañete, Gaia Gallo, Noah Agada, Wen Xu, Mark C. Genovese   +7 more
doaj   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis

Rheumatology and Therapy
Introduction A previous network meta-analysis established 16-week relative efficacy with bimekizumab, an inhibitor of interleukin (IL)-17F in addition to IL-17A, versus other treatments for patients with radiographic axial spondyloarthritis (r-axSpA; i.e.
Walter P. Maksymowych, Howard Thom, Michael F. Mørup, Vanessa Taieb, Damon Willems, Nikos Lyris, Karl Gaffney   +6 more
doaj   +1 more source

Fournier Gangrene in a Patient Receiving Ixekizumab Therapy

Annals of Internal Medicine: Clinical Cases
We report a case of a 42-year-old man who developed Fournier gangrene while undergoing treatment of psoriatic arthritis with the interleukin-17 inhibitor ixekizumab (Taltz).
Lucas Gunnels, Michael Kleinman
doaj   +1 more source